Lapatinib, a small molecule dual inhibitor of EGFR and HER2, is another therapeutic option for HER2-positive breast cancer patients [36-38], although it offers only a 4.3% response rate in patients with HER2-positive breast cancer when used as monotherapy [39-41]. Here, EGFR is linked to breast carcinoma.